Maxim Group Starts SciClone Pharmaceuticals (SCLN) at Buy

November 28, 2016 5:41 PM EST Send to a Friend
Maxim Group initiates coverage on SciClone Pharmaceuticals (NASDAQ: SCLN) with a Buy rating and a price target of $14.00.Analyst Gabrielle ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login